Parkinson's disease (PD) symptoms do not become apparent until most dopaminergic neurons in the substantia nigra pars compacta (SNc) degenerate, suggesting that compensatory mechanisms play a role. Here, we investigated the compensatory involvement of activated microglia in the SN pars reticulata (SNr) and the globus pallidus (GP) in a 6-hydroxydopamine-induced rat hemiparkinsonism model. Activated microglia accumulated more markedly in the SNr than in the SNc in the model. The cells had enlarged somata and expressed phagocytic markers CD68 and NG2 proteoglycan in a limited region of the SNr, where synapsin I-and postsynaptic density 95-immunoreactivities were reduced. The activated microglia engulfed pre-and post-synaptic elements, including NMDA receptors into their phagosomes. Cells in the SNr and GP engulfed red fluorescent DiI that was injected into the subthalamic nucleus (STN) as an anterograde tracer. Rat primary microglia increased their phagocytic activities in response to glutamate, with increased expression of mRNA encoding phagocytosis-related factors. The synthetic glucocorticoid dexamethasone overcame the stimulating effect of glutamate. Subcutaneous single administration of dexamethasone to the PD model rats suppressed microglial activation in the SNr, resulting in aggravated motor dysfunctions, while expression of mRNA encoding glutamatergic, but not GABAergic, synaptic elements increased. These findings suggest that microglia in the SNr and GP become activated and selectively eliminate glutamatergic synapses from the STN in response to increased glutamatergic activity. Thus, microglia may be involved in a negative feedback loop in the indirect pathway of the basal ganglia to compensate for the loss of dopaminergic neurons in PD brains. 2.2 | 6-Hydroxydopamine (6-OHDA)-induced hemiparkinsonism rat model 
80% depletion of striatal dopamine (DA) and 50 or 60% loss of DArgic neurons in the SNc, in humans as well as PD animal models (Bernheimer, Birkmayer, Hornykiewicz, Jellinger, & Seitelberger, 1973; Bezard, Gross, & Brotchie, 2003; Choudhury et al., 2011b; Perez, Parameswaran, Huang, O'Leary, & Quik, 2008; Zigmond, Abercrombie, Berger, Grace, & Stricker, 1990) . This suggests that compensatory mechanisms counteract the decrease in DA content in the striatum and prevent the appearance of PD symptoms.
An increment of DA release and enhanced axonal sprouting of DArgic neurons in the SNc have been implicated as compensatory mechanisms in the PD brain (Arkadir, Bergman, & Fahn, 2014) .
Enhanced DA turnover in the striatum, reflecting increased presynaptic DArgic activity, may also be responsible for the compensation (Perez et al., 2008) . Upregulated D2 receptor activity, upregulated enkephalin expression, altered activities of neurons in the cerebral cortex, and various other mechanisms have been postulated to compensate for DArgic neuron loss in PD (Bezard, Boraud, Bioulac, & Gross, 1997; Bezard et al., 2003) . However, compensation for PD pathophysiology may not be fully explained by these neuron-based mechanisms.
There are two pathways in the basal ganglia, direct and indirect, and these are thought to play critical roles in the pathogenesis of PD, although their precise roles are still to be elucidated (Calabresi, Picconi, Tozzi, Ghiglieri, & Di Filippo, 2014) . Glutamatergic neurons in the subthalamic nucleus (STN), which belongs to the indirect pathway, increase their activity in response to decreases in DA release in the striatum.
The increased glutamatergic transmission causes activation of the basal ganglia outputs, the globus pallidus pars interna (GPi) and SN pars reticulata (SNr), leading to inhibition of the thalamus and neurological disabilities.
Microglial cells express glutamatergic receptors that alter their function and morphology (Domercq, Vazquez-Villoldo, & Matute, 2013; Fontainhas et al., 2011; Murugan, Ling, & Kaur, 2013; Noda, Nakanishi, Nabekura, & Akaike, 2000) . Elimination of synapses by the phagocytic actions of microglia, also known as synaptic pruning or stripping, has recently been well described in healthy and disease states (Kettenmann, Kirchhoff, & Verkhratsky, 2013; Wake, Moorhouse, Miyamoto, & Nabekura, 2013) . On the basis of these previous studies, we examined the possible involvement of microglia in compensating for PD pathogenesis by eliminating glutamatergic efferents with increased neuronal activity from the STN.
| M A TE RI A L S A ND M E TH ODS

| Animals
Male Wistar rats (7-8 weeks old; body weight 250-270 g) were housed two rats per cage under standard laboratory conditions. All rats were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, 1996) . All animal experiments were carried out in accordance with the Guidelines for Animal Experimentation of Ehime University Graduate School of Medicine.
2.2 | 6-Hydroxydopamine (6-OHDA)-induced hemiparkinsonism rat model A 6-OHDA-induced hemiparkinsonism rat model was prepared as described elsewhere (Choudhury et al., 2011b) . The 6-OHDA (SigmaAldrich, St. Louis, MO) was dissolved in saline containing ascorbic acid (Wako, Osaka, Japan) (10 mg mL 21 dissolved in 1% ascorbate-saline) and injected into the right striatum. The 6-OHDA-induced PD rat models were selected for further studies by assessing apomorphineinduced rotation at 5-days post lesioning (dpl) (Metz, Tse, Ballermann, Smith, & Fouad, 2005) . Apomorphine (Kyowa Kirin, Tokyo, Japan) was subcutaneously administered to the 6-OHDA-treated rats at a dose of 2 mg kg
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. The high dose was necessary to induce the abnormal rotational movement at the early time point after lesioning (Zhang, Zhang, Liu, & Wang, 2017) . Five minutes after the administration, the rats were individually placed into a 40-cm-diameter bowl and the clockwise (contralateral) rotations were monitored through 10-min-video recording. Only rats that turned more than 30 times in 10 min were considered as PD model.
| Immunohistochemical staining
The primary antibodies listed in Supporting Information Table 1 were used for indirect immunohistochemical staining (Sugimoto et al., 2014) .
Anesthetized rats were fixed by perfusion with 4% paraformaldehyde containing 2 mM MgCl 2 for 10 min. The fixed brains were sliced into 10-mm-thick coronal sections at three levels: the globus pallidus level
(1 mm posterior from bregma), the STN level (3.5 mm), and the SN level (5 mm). After incubation with the primary antibodies, the sections were incubated with DyLight 488, DyLight 549, and/or DyLight 649-labeled secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Hoechst 33342 (Sigma-Aldrich) was used for nuclear staining. The results were observed with a Nikon A1 confocal laser scan microscope (CLSM; Tokyo, Japan) or a scanning fluorescence microscope (BZ-9000; Keyence, Osaka, Japan). The images were processed for morphometrical analyses using Adobe Photoshop CS5
Extended (Adobe Systems, San Jose, CA) and ImageJ 1.43u (Wayne Rasband, National Institute of Health, Bethesda, MD) (Choudhury et al., 2011b) .
| Immunoblotting
Rats were sacrificed at 7 dpl. The ventral midbrain containing the SN (midbrain delineated longitudinally 4.5-6.6 mm from bregma, perpendicularly 7 mm from the skull) was subdivided into the right and the left sides, which were lysed and processed for electrophoresis. The lysates were electrophoresed and transferred to nitrocellulose membranes, which were incubated with the primary antibodies listed in Supporting Information Table 1 . The immunoreaction was visualized as described previously (Tanaka et al., 1998) . Densitometrical analyses were performed using ImageJ 1.43u. The data were standardized to b-actin immunoreactivity.
| Quantitative real-time RT-PCR (qPCR)
The ventral midbrain tissues containing the SN were dissected out for qPCR experiments similarly to the dissection procedure for immunoblotting described in Section 2.4. The tissues were homogenized in ISOGEN (Nippon gene, Tokyo, Japan) using an ultrasonic cell disruptor.
Cultured microglial cells in poly-L-lysine (PLL)-coated four-well culture plates were also homogenized in ISOGEN and the total RNA collected.
cDNA was obtained from DNase-I-treated RNA by reverse transcription using an oligo-(dT) 15 primer, (Matsumoto et al., 2015) . cDNA was diluted 1:3, and triplicate volumes of 1 mL were used for qPCR on an MJ mini instrument (Bio-Rad, Hercules, CA) using Fast Start Universal SYBR Green (Roche Diagnostic Japan, Tokyo, Japan). All gene-specific mRNA expression measurements were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA level. The primer sequences for each gene are listed in Supporting Information Table 2 .
| Anterograde tracing
Anterograde labeling of neuronal projections from the STN to the GP or the SNr with 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiIC18(3); DiI; Molecular Probes, Eugene, OR), a fluorescent lipophilic cationic indocarbocyanine dye, was performed as described elsewhere (Murphy and Fox, 2007 ) with significant modifications. Five days after 6-OHDA-treatment, 2 mL of 0.3% DiI dissolved in ethanol was injected into the STN with a 28-gauge Hamilton syringe at 3.7 mm posterior, 2.5 mm lateral to bregma, and 8.5 mm ventral to the surface of the brain. The injection rate was 1 mL min
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. After the injection, the syringe was left in place for an additional 5 min before being retracted slowly (1 mm min
). The rats were fixed as described above, 48 h after the DiI injection and the fixed brains cryosectioned at the SN and the GP level and used for immunohistochemical staining.
| Rat primary microglial cultures
Rat primary microglial cultures were prepared as described previously (Tanaka et al., 1998 
| Phagocytosis assay
The phagocytic activity of cultured microglia was evaluated using a PKH26 red fluorescent phagocytic cell linker kit (Sigma-Aldrich) as described elsewhere (Sawada et al., 1998; Yokoyama et al., 2004 
| Rota-rod test
Motor coordination and balance were tested using a rota-rod (Ugo Basile, Rota-rod 7750, Italy) as described elsewhere (Choudhury et al., 2011b) . Rats were pretrained 1, 3, and 5 days before, and 3 and 5 days after, 6-OHDA injections. The speed of the rota-rod was 40 rpm over a 300-s period. Dex (3 mg kg
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, s.c.) or minocycline (Sigma-Aldrich; 50 mg kg
, i.p.) (Quintero et al., 2006) was administered to the rats on 6 dpl. The following day (24 h later), the rota-rod test was performed by placing the rats on a rotating drum and measuring the time each animal took to fall (Dekundy, Lundblad, Danysz, & Cenci, 2007) . The test was done between 20:00 and 21:00.
| Open-field test
The open-field test was employed to evaluate neurological dysfunction.
A square open-field (10,000 cm 2 ) with walls (50 cm in height) equipped with a video-tracking system (Ethovision XT 7, Noldus Info. Tech., Wageningen, The Netherlands) was used. Dex or minocycline was administered as described in Section 2.10 on 6 dpl. On the following day, the rats were placed at the corner of the open-field for a single
5-min session with the experimenter out of view. This experiment was conducted between 10:00 and 12:00 h and each animal was tested only once. The rats were allowed 1 min to acclimate to the unfamiliar field then the distance traveled and moving velocity were recorded for 3 min. After each trial, fecal boli were removed and the floor was wiped with a damp cloth and dried.
| Preparation of synaptosomal fractions
To isolate synaptosomes, prefrontal cortices and the ventral midbrains containing SN were sampled, weighed, dounced in a grinder and centrifuged using Syn-PER synaptic protein extraction reagent (Thermo Scientific, Rockford, IL), according to manufactural instructions. In brief, immediately before use, protease inhibitor and phosphatase inhibitor cocktail-2 (Sigma, St. Louis, MO) was added to the Syn-PER reagent.
Brain samples were dounced using Syn-PER synaptic protein extraction reagent at a volume ratio of ten using a Dounce tissue homegenizer with 10 up and down even slow strokes. The homogenates were centrifuged at 1,200g with 48C for 10 min to remove cell debris. The resulting supernatant was centrifuged at 15,000g with 48C for 20 min.
The synaptosome pellets were collected and served for qPCR and immunoblotting.
| Statistical analysis
Data expressed as means 6 standard error of the mean (SEM) or standard deviation (SD) were statistically analyzed using InStat3 software (GraphPad Software, La Jolla, CA). Data were subjected to two-tailed Student's t tests (unpaired) or a two-way ANOVA with Tukey's posthoc test. Significance was set at p < 0.05.
| R E SU LTS
| Activated microglia in the SNr
Microglial activation in the SNc has been well described not only in PD animal models but also in PD patients' brains (Choudhury et al., 2011b; McGeer and McGeer, 2008) . Activation of microglial cells, however, appeared more apparent in the SNr than in the SNc at 7 days post lesion (dpl) with 6-OHDA, as revealed by CD11b-immunofluorescence staining ( Figure 1 ). We injected 6-OHDA only into the right striatum and compared CD11b-immunoreactivity in the contralateral (left) and ipsilateral (right) sides. Tyrosine hydroxylase (TH) immunoreactivity in the SNc was reduced in the ipsilateral (right) side, and some activated microglia were present in the SNc ( Figure 1A ; arrowheads). However, there were far more activated microglia with enlarged CD11b were all suppressed in the right ventral midbrain. All other subtypes of NMDA, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and mGlu receptors had no significant change in their mRNA expression (Supporting Information Figure 2 ). In addition, synaptosomal fractions contained abundant amount of mRNA for synaptic proteins and glutamate receptors (Supporting Information Figure 3 ) as has been described (Martin, 2004; Steward and Schuman, 2001 ). GABA A receptor g2 subunit (GABA-ARg) mRNA is upregulated in the right ( Figure   2Ch ) in accordance with a previous report (Yu, Wang, Liu, & Yin, 2001) , whereas the expression level of GABA B receptor 1 (GABA-BR; Figure   2Ci ) and 2 (data not shown) mRNA was very low. The 6-OHDA administration did not cause significant changes in GABA-BR mRNA.
3.2 | Decrease in synaptic elements in the SNr region with accumulation of activated microglia
The activation of microglia did not occur in the whole right SNr but in only a limited region (Figure 3) . Although the area of microglial activation in the SNr varied between animals (cf., Figures 1A, 3A ,B, and 4, data from different animals), the decrease in the expression of the presynaptic protein synapsin I ( Figure 3A ) and a postsynaptic protein, postsynaptic density protein 95 (PSD95; Figure 3B ), was observed in 
| Activated microglia phagocytosed STN-derived synaptic elements
Three-dimensional observation with CLSM showed that microglia often intimately attach to, what are presumably, GABArgic neurons in the SNr ( Figure 4A ). The attachment of microglia may indicate synaptic stripping (Kettenmann et al., 2013) . In such microglial somata, NeuN 1 materials were found in the CD68 1 phagosomes (Figure 4Ab, arrows) .
Moreover, synaptophysin-immunoreactivity was localized in the simultaneously. Dex overcame the effect of Glu on phagocytosis (Figure 6D-F) . Glu enhanced the expression of mRNA encoding the microglial markers Iba1, CD11b, and CX3CR1 (Liu et al., 2015) (Figure 6Ga Gc). Glu also increased mRNA encoding F4/80 (Lin et al., 2005) , CD68 (Sugimoto et al., 2014) , matrix metalloproteinase 2 (MMP2) (Lively and Schlichter, 2013) , cathepsin S (Hayashi et al., 2013; Lively and Schlichter, 2013) , and interferon regulatory factor 1 (IRF1) (Higaki et al., 2016) ( to rats at 8 pm at 6 dpl, and the rats were subjected to perfusion fixation 19-20 h later. As shown in Figure 7A TNFa, in addition to suppressing microglial markers and the phagocytosis-related factors Iba1, CD68, and cathepsin S ( Figure 7D ,E).
Importantly, Dex increased the mRNA expression of synaptic markers and Glu receptors ( Figure 7F,G) . However, Dex decreased GABA-AR and GAD mRNA ( Figure 7H ) as well as CD47 and a CD47-binding protein signal regulatory protein a (SIRPa) ( Figure 7I ) that mediates the "don't eat-me" signal on innate immune cells including microglia (Brown and Frazier, 2001; Zhang, Li, Yang, Chen, & Hu, 2015) . Conversely, Dex administration did not significantly affect the mRNA expression of factors mediating the "eat-me" signal (Supporting Information Figure 5 ) (Brown and Neher, 2014) .
To see the effects of Dex administration on the neurological symptoms of 6-OHDA-treated rats, rota-rod and open-field tests were performed 16 or 24 h after Dex administration, respectively. The rota-rod test revealed that Dex administration aggravated motor coordination ( Figure 7J ), while vehicle-administered rats did not show significant motor deficits in this test. Dex also reduced the total moved distance (Figure 7Ka ), the mobile frequency (Figure 7Kb) , and the moving velocity (Figure 7Kc ) of the rats as revealed by the open-field test. Minocycline has been well characterized of its suppressive effects on proinflammatory activation of microglial cells (Tikka, Fiebich, Goldsteins, Keinanen, & Koistinaho, 2001 ) and also shown of its ameliorative effects on PD animal models (Du et al., 2001; Quintero et al., 2006) when it was continuously administered. Therefore, minocycline (50 mg kg
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) was administered once at 6 dpl similarly to Dex. However, it did not suppress the microglial morphological activation and expression of CD68, and also did not deteriorate 6-OHDA-induced motor deficits (Supporting Information Figure 6 ).
As a compensatory mechanism for DArgic neuron loss, increased DA turnover in the striatum has been thought to play a role (Perez et al., 2008) . To evaluate whether Dex administration affected the contents or turnover of DA, the concentration of DA and its metabolites in the striatum were measured using HPLC ( Figure 7L ). The 6-OHDA treatment markedly reduced DA contents in the striatum regardless of Dex administration. Although Dex showed a tendency to increase DA contents in the right striatum (Dex, 0.313 6 0.290 mg mg 21 wet tissue weight vs. control, 0.174 6 0.172; (mean 6 SD; n 5 6 and 7, respectively; Figure 7La ), the increase was not significant. Furthermore, Dex administration did not affect DA turnover calculated as the (HVA 1 DOPAC)/DA ratio in the right striatum (Figure 7Lb ). Extra- (Figure 7Lc ) and intra- (Figure 7Ld ) cellular turnover (Perez et al., 2008) , calculated as the HVA/dopamine and the DOPAC/dopamine ratios, respectively, were also not significantly changed.
| D I SCUSSION
We Microglia express a variety of glutamatergic receptors (Domercq et al., 2013; Murugan et al., 2013; Pocock and Kettenmann, 2007) Activation of astrocytes in PD brains has been reported (Choudhury et al., 2011a,b) . Astrocytes express reuptake glutamate transporters EAATs 1 and 2, while playing a critical role in the removal of extracellular glutamate (Robinson and Jackson, 2016) . Therefore, it might be possible that astrocytic glutamate transporters contribute to the compensation mechanism by reducing the hyperactive STNderived glutamate levels in the basal ganglia outputs. However, GFAP- Figure 7) . Furthermore, expression levels of mRNA for GFAP, EAAT1 (GLAST) and EAAT2 (GLT-1)
were not different between in the left and the right ventral midbrain samples. Moreover, the neuronal reuptake transporter EAAC1 mRNA expression was also not changed. These data suggest that the glutamate transporters may not play significant roles to abolish the deteriorating effects of hyperactive STN neurons.
The majority of PD patients are aged people with the incidence rate for PD increasing from 0.3 per 1000 person-years in subjects aged 55 to 65 years, to 4.4 per 1000 person-years for those aged 85 years (de Lau et al., 2004) . While aging, microglia display senescent changes in their phenotypes, such as increased proinflammatory reactions and decreased phagocytic and chemotactic activities (Rawji et al., 2016; Streit, Braak, Xue, & Bechmann, 2009 ). The deficits of senescent microglia in phagocytic activity might be related to the increased incidence of PD in aged subjects. Presumably this is because the senescent cells can no longer compensate for the reduction of DA in the striatum by eliminating glutamatergic synapses from the hyperactive STN.
The synthetic glucocorticoid Dex has a strong suppressive effect on activated microglial cells as shown in this study and elsewhere (Carrillo-de Sauvage et al., 2013; Higaki et al., 2016; Tanaka et al., 1997) .
Dex inhibits Glu-stimulated phagocytosis and mRNA expression for The most critical point for the hypothesis shown in Figure 8 is that activated microglia in the SNr selectively eliminates glutamatergic synapses from the hyperactive STN in the indirect pathway, but not the GABArgic synapses from the striatum in the direct pathway. In this study, glutamatergic receptor mRNA levels decreased, whereas expression of GAD and GABA-AR mRNA or protein were maintained or elevated. Conversely, when microglial phagocytosis was suppressed by Dex administration, glutamatergic receptor mRNA expression increased, and GAD and GABA-AR mRNA expression was suppressed ( Figure 7) . The results support the notion of the selective elimination of glutamatergic synapses by microglial cells. Dex administration suppressed expression of CD47 and SIRPa mRNA, which mediate "don't eat-me" signals, whereas expression of molecules mediating "eat-me" signals, such as GAS6 or complements C1q and C3, were not significantly affected (Supporting Information Figure 3 ) (Brown and Frazier, 2001; Brown and Neher, 2014; Zhang et al., 2015) . This suggests the possibility that GABArgic synapses are protected by the "don't eat-me" signals mediated by CD47 and SIRPa. It has been reported that microglial cells selectively eliminate inactive synapses in the developing brain through complement or "eat-me" signal-dependent manners (Schafer et al., 2012; Wake et al., 2013) . This study demonstrates the selective Whether different mechanisms underlie the elimination of inactive and hyperactive synapses in developing and pathologic brains remains to be elucidated.
In conclusion, microglial activation occurs in the SNr and the GP devoid of neuronal degeneration. Activated microglia eliminate glutamatergic synapses through phagocytosis in response to increased Glu release from STN neurons, resulting in suppression of the hyperactivity of the indirect pathway in the basal ganglia and alleviation of PD symptoms. Subthalamotomy has long been performed as a neurosurgical treatment for PD (Alvarez et al., 2005; Bergman, Wichmann, & DeLong, 1990; Calabresi et al., 2014) , aiming to abolish STN hyperactivity. The present study suggests that activated microglia in the output structures may exert, at least in part, the same effect as subthalamotomy.
